UNSPSC 51111619: Brequinar

This classification denotes a pyrimidine antagonist and dihydroorotate dehydrogenase inhibitor with the molecular formula C23H15F2NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 5XL19F49H6 chemically known as 4-quinolinecarboxylic acid, 6-fluoro-2-(2'-fluoro(1,1'-biphenyl)-4-yl)-3-methyl- but generally known as brequinar, which bears US NIH Compound Identifier 57030. European Medicines Agency schedules Brequinar in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05885MIG.

UNSPSC 51111619 Brequinar, a Commodity code, addresses procurement of brequinar, an immunosuppressive pharmaceutical compound used in transplant and autoimmune applications. State and local governments do not typically purchase brequinar directly; this code appears in state and local procurement databases primarily when health systems, hospital networks, or pharmaceutical procurement cooperatives tag bulk pharmaceutical acquisitions or when state Medicaid agencies structure inventory contracts that nominally include a broad formulary. The actual purchasing activity under this code at the state and local level is minimal and episodic, driven by clinical demand rather than routine procurement cycles.

The source does not identify recent state or local solicitations, issuing bodies, geographic regions, or response dates for brequinar procurement. Without posted opportunities to characterize issuing-body mix, geographic concentration, or representative RFPs or RFQs, this code shows no active state and local buying signals at present. Brequinar remains a specialty pharmaceutical with limited market adoption, and state and local procurement offices rarely issue standalone solicitations for it. Any acquisition typically occurs as a line item within larger pharmaceutical or GPO-sourced contracts rather than as a distinct procurement action.